• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Remote Care Management Platform MedArrive Raises $8M

Share:

April 17, 2023

MedArrive, a care management platform that provides in-home healthcare services, has received an $8 million strategic investment from Cobalt Ventures, a subsidiary of Blue Cross and Blue Shield of Kansas City. The investment brings the company’s total raise to $40.5 million. MedArrive plans to expand its platform and team, increase its work with payers, and expand into new markets. The company has partnerships with Superior HealthPlan, Brave Health, and Ouma Health to offer Texans in-home healthcare, virtual behavioral health services, telehealth, and mother and fetal in-home care offerings to women on Medicaid.

MedArrive, a care management platform that merges telehealth and in-person care, announced it received an $8 million strategic investment from Cobalt Ventures, a Blue Cross and Blue Shield of Kansas City subsidiary.

The round brings the company’s total raise to $40.5 million.

WHAT IT DOES

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

MedArrive offers a provider network of paramedics, EMTs and other healthcare providers who visit patients on behalf of their health insurance plan, providing in-home healthcare services, diagnostics, health assessments and preventative health measures. The company also assists with transportation, nutrition and mobility.

With the new investment, the company will increase its work with payers, grow its team, build its platform and expand into new markets.

MARKET SNAPSHOT

In 2021, MedArrive scored $25 million in Series A funding, joining the numerous companies that garnered investment that year.

However, venture funding decreased in 2022. Dan Trigub, MedArrive’s CEO and cofounder, described the year’s complicated financing environment to MobiHealthNews in December.

“This year’s funding environment quickly separated the ‘good’ from the ‘bad,’ meaning businesses built with poor unit economics on day one will not survive. It also forced companies to explore other funding alternatives like venture debt or taking down rounds. Founders and executive teams leaned into being more diligent with capital and planned for the worst,” Trigub said.

That same month, MedArrive revealed its plans to partner with Texas-based Superior HealthPlan and virtual mental health company Brave Health to allow Texans to access in-home healthcare, virtual behavioral health services and telehealth.

Last month, the remote care company announced a partnership with maternity telehealth platform Ouma Health to scale its mother and fetal in-home care offerings to women on Medicaid.

Source: MobihealthNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Merck Buys Animal Health Company AntelliqMerck Buys Animal Health Company Antelliq
  • Cesca Therapeutics Acquires Remaining Ownership Stake in ThermoGenesis and Forms New ThermoGenesis Subsidiary, CARTXpress Bio, Inc., to Focus on its CAR-TXpress Cellular Processing PlatformCesca Therapeutics Acquires Remaining Ownership Stake in ThermoGenesis and Forms New ThermoGenesis Subsidiary, CARTXpress Bio, Inc., to Focus on its CAR-TXpress Cellular Processing Platform
  • Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private PlacementAadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
  • FDA roundup: The major device, app, and algorithm approvals of 2018 (so far)FDA roundup: The major device, app, and algorithm approvals of 2018 (so far)
  • Eurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and ExpertiseEurofins Scientific Announces Acquisition of Beacon Discovery, Substantially Expanding Its Integrated Drug Discovery Capabilities and Expertise
  • Philips Expands its Digital Pathology Solutions Portfolio with the Acquisition of PathXLPhilips Expands its Digital Pathology Solutions Portfolio with the Acquisition of PathXL
  • Andhra Medical College Tries Out AI Platform for Lung Health AssessmentAndhra Medical College Tries Out AI Platform for Lung Health Assessment
  • Invitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of AcquisitionInvitae Reports Inducement Grants Under NYSE Rule 303A.08 to Former Employees of Singular Bio, Inc. in Connection with Closing of Acquisition

Trending This Week

  • Novartis Drops Eye Disease Gene Therapy from $800M Gyroscope Acquisition
  • GSAC Engineering Acquires Key Intellectual Property and Assets from Duos Technologies GroupGelStat’s Subsidiary, GSAC Engineering, Launches Intelligent Correctional Facilities Automation Systems (iCAS) in the Industrial Security Market
  • Life Launches AI Clinical Trial Matching Assistant for Cancer
  • 79% of Healthcare Execs Believe Most Drug Diversion Goes Undetected
  • Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine
  • FDA Releases Updated Final Guidance for its Breakthrough Devices Program

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications